CSIMarket Company Name, Ticker, Industry, else..
 
Climb Bio Inc   (NASDAQ: CLYM)
 
Price: $15.6950 $-0.20 -1.289%
Day's High: $16.173500061035156 Week Perf: 4.29 %
Day's Low: $ 15.51 30 Day Perf: 15.92 %
Volume (M): 566,065 52 Wk High: $ 18.33
Volume (M$): $ 0 52 Wk Avg: $7.46
Open: $15.82 52 Wk Low: $1.54



 Market Capitalization (Millions $) 1,195
 Shares Outstanding (Millions) 76
 Employees 29
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -58
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a clinical-stage biotechnology firm developing therapeutics for immune-mediated diseases through the acquisition or licensing of product candidates with strong biological rationale. Its lead product, budoprutug, is an anti-CD19 monoclonal antibody in clinical trials for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. The company is also developing CLYM116, an anti-APRIL monoclonal antibody targeting IgA nephropathy and other B-cell mediated diseases.


   Company Address: 20 William Street Wellesley Hills 2481 MA
   Company Phone Number: 857-2596   Stock Exchange / Ticker: NASDAQ CLYM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALKS   -3.79%    
AXSM        4.68% 
BMRN   -0.56%    
RYTM   -3.9%    
VNDA   -2.86%    
ZYME   -7.58%    
• View Complete Report
   



Clinical Study

Climb Bio Ascends Innovating IgAN Treatment While Bolstering Financial Resilience,

Published Mon, Oct 20 2025 11:14 AM UTC

Navigating Breakthroughs: Climb Bio s Strategic Advances in IgA Nephropathy Treatment Climb Bio Inc. is poised to make an impressive mark at the forthcoming American Society of Nephrology (ASN) Kidney Week 2025. The company is set to present promising preclinical data concerning CLYM116, an innovative anti-APRIL monoclonal antibody, showcasing its favourable pharmacokinetic ...
Management Announcement

Climb Bio to Unveil Strategic Focus on Immune-Mediated Diseases and Budoprutug Development in Virtual Investor Update,

Published Tue, Oct 15 2024 11:00 AM UTC

IntroductionClimb Bio, a biopharmaceutical company, is preparing to share significant updates regarding its lead product candidate, Budoprutug, and its strategic focus on immune-mediated diseases during an upcoming virtual investor event. The transition marks a decisive shift in the company’s operational focus and promises to position Climb Bio as a leader in the developme...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 4.99
PEG (TTM) -

Financial Strength Current
Quick Ratio 30.86
Working Capital Ratio 31.5
Leverage Ratio (MRQ) 0.03
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.83 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 2.4 $
Book Value 3.15 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,987,034
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.